Risk Of Developing Liver Cancer After HCV Treatment

Friday, January 9, 2015

Hepatitis C Update-Treatment Of Genotypes 1,2,3,4,5,and 6

HCV Treatment and Genotypes 

Good day folks, we have a few website updates from Hepatitis C Online, an interactive website from the University of Washington.

The site has comprehensive information on the diagnosis, monitoring, treatment and management of hepatitis C and offers a free online Hepatitis C Course, using AASLD/IDSA/IAS-Recommendations for Testing, Managing, and Treating Hepatitis C.

The hepatitis C patient will have an opportunity to the explore over 7 different modules, slide lectures, and read key data from published studies using new direct-acting antiviral agents.

Updated January 9 2015 
This month, Hepatitis C Online updated Module 5;Treatment of Chronic Hepatitis C Infection.

Click on each lesson to review the course module, or download PDF, I highly suggest the latter for easy viewing.

Genotype 1
PDF - Treatment of HCV Genotype 1
Lesson 1: Treatment of HCV Genotype 1
Contents: Introduction
Genotype 1: Initial Treatment and Retreatment with Prior Relapse
Genotype 1: Retreatment of Patients with prior Treatment Failure
Genotype 1: Future Treatment Options
Summary Points
Reference

Genotype 2
Contents: Introduction
Genotype 2: Initial Treatment and Retreatment with Prior Relapse
Genotype 2: Retreatment of Prior Nonresponders
Genotype 2: Future Treatment Options
Summary Points

Genotype 3
PDF - Treatment of HCV Genotype 3
Lesson 3: Treatment of HCV Genotype 3
Contents: Introduction
Genotype 3: Initial Treatment and Retreatment with Prior Relapse
Genotype 3: Retreatment of Prior Nonresponders
Genotype 3: Future Treatment Options
Summary Points

Genotype 4
Contents: Introduction
Genotype 4: Initial Treatment and Retreatment with Prior Relapse
Genotype 4: Retreatment of Prior Nonresponders
Genotype 4: Future Treatment Options
Summary Points

Genotype 5 or 6
Genotype 5 or 6: Initial Treatment and Retreatment with Prior Relapse
Genotype 5 or 6: Retreatment of Prior Nonresponders
Genotype 5 or 6: Future Treatment Options
Summary Points

Index
Genotypes 1-6
Module 5; Treatment of Chronic Hepatitis C Infection

Liver International
Volume 35, Issue Supplement s1, pages 1–3, January 2015

A special supplement of Liver InternationalProceedings of the 8th Paris Hepatitis Conference International Conference on the Management of Patients with Viral Hepatitis, is open access this month. This issue will include review articles on both HCV and HBV, with treatment strategies for HCV genotype 2, 4, and HCV-1b. Additional articles include HIV/HCV co-infection, end stage liver disease, liver cancer, and the dire universal need for affordable IFN-free regimens. 

Highlights
Optimal IFN-free therapy in treatment-naïve patients with HCV genotype 1 infection
Optimal therapy in genotype 4 chronic hepatitis C: finally cured?
Optimal therapy of genotype-2 chronic hepatitis C: what's new?
How to optimize current therapy in hepatitis C virus genotype 1 patients. Predictors of response to interferon-based therapy with second wave direct acting antivirals
Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C

In Case You Missed It

November 2014
Hepatitis C Genotype 3
Written by Mr. Alan Franciscus, published in HCV Advocate's November Newsletter.
In the past, HCV genotype 3 was thought to be one of the easiest to cure. As a result there was little incentive to develop newer therapies especially since there were fewer people with genotype 3 in developed countries. Now it has turned out that treatment of genotype 3 is the hardest to cure with HCV inhibitor therapy compared to HCV genotypes 1, 2 and 4. 

Of Interest
AASLD @ HepMag.com
Eight weeks of Gilead Sciences’ Sovaldi and GS-5816, with or without ribavirin, cured high rates of people with genotype 3 of hepatitis C virus (HCV), but yielded unsatisfactory results among those with genotypes 1 and 2.

Genotypes 3 and 6
Harvoni Posts Good Cure Rates for Hepatitis Genotypes 3 and 6
Twelve weeks of Gilead Sciences’ Harvoni (ledipasvir/sofosbuvir) plus ribavirin cured 73 percent to 89 percent of people with genotype 3 of hepatitis C virus (HCV), while 96 percent of people with genotype 6 were cured without ribavirin in a recent trial, the National AIDS Treatment Advocacy Project (NATAP) reports.

Insulin resistance and liver steatosis in HCV genotype 3
Three main types of steatosis in the patients with Hepatitis C virus (HCV) infection are known: a metabolic type associated with metabolic syndrome and two viral types: one that seems to be directly triggered by the virus and one that could originate from the interference of the virus in the mechanisms of insulin resistance. The first viral type is particularly widely considered to be predominant and, perhaps, strictly linked to HCV genotype 3 infection and its intra-hepatic viral load. This evidence is supported by the resolution of steatosis in most patients infected with genotype 3 virus after HCV eradication by antiviral therapy.

Enjoy the weekend!
Tina

No comments:

Post a Comment